Background: Myasthenia gravis (MG) is an autoantibodies-mediated
autoimmune disease with the complications of neuromuscular junction transmission.
In this study, we aimed to investigate the molecular regulatory roles of pentaxin
3 (PTX3) in patients and in animal model with MG and to explore its underlying
mechanism. Methods: Patients with MG were identified and enrolled at our
designated hospital and animal model was utilized for the proposed study. Enzyme-linked immunosorbent assay (ELISA)
kit were used to quantify the IL-1
Announcements
Open Access
Original Research
Serum Pentaxin 3 (PTX3) Promotes NLRP3 Inflammasome and Pyroptosis in Patients with Up-Regulated Myasthenia Gravis
Show Less
1
Department of Neurology, Beijing Friendship Hospital, Capital Medical University, 100050 Beijing, China
2
Department of Neurosurgery, Beijing ChaoYang Hospital, Capital Medical University, 100020 Beijing, China
*Correspondence: yongbozhang@ccmu.edu.cn (Yongbo Zhang)
Front. Biosci. (Landmark Ed) 2023, 28(11), 306;
https://doi.org/10.31083/j.fbl2811306
Submitted: 21 February 2023 | Revised: 10 March 2023 | Accepted: 5 May 2023 | Published: 28 November 2023
(This article belongs to the Special Issue Inflammation and fibrosis: from molecular mechanisms to therapeutic opportunities)
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract
Keywords
myasthenia gravis
NLRP3
inflammasome
PTX3
neuromuscular disease
Figures
Fig. 1.